Temozolomide Resistance in Glioblastoma by NRF2: Protecting the Evil

The transcription factor NRF2 is constitutively active in glioblastoma, a highly aggressive brain tumor subtype with poor prognosis. Temozolomide (TMZ) is the primary chemotherapeutic agent for this type of tumor treatment, but resistance to this drug is often observed. This review highlights the re...

Full description

Bibliographic Details
Published in:	Biomedicines
Main Authors:	Karoline Almeida Lima, Isabeli Yumi Araújo Osawa, Maria Carolina Clares Ramalho, Izadora de Souza, Camila Banca Guedes, Cláudio Henrique Dahne de Souza Filho, Linda Karolynne Seregni Monteiro, Marcela Teatin Latancia, Clarissa Ribeiro Reily Rocha
Format:	Article
Language:	English
Published:	MDPI AG 2023-04-01
Subjects:	NRF2 glioblastoma temozolomide
Online Access:	https://www.mdpi.com/2227-9059/11/4/1081

Similar Items

Revealing Temozolomide Resistance Mechanisms via Genome-Wide CRISPR Libraries
by: Clarissa Ribeiro Reily Rocha, et al.
Published: (2020-12-01)

Temozolomide in treatment resistant prolactinomas
by: V. N. Shree, et al.
Published: (2018-08-01)

Quinacrine enhances temozolomide cytotoxicity in temozolomide-sensitive and -resistant glioblastoma cells
by: Pingde Zhang, et al.
Published: (2018-01-01)

Importance of Autophagy Regulation in Glioblastoma with Temozolomide Resistance
by: Young Keun Hwang, et al.
Published: (2024-08-01)

Temozolomide for aggressive pituitary tumors:-A literature review
by: Hu Hui-zheng, et al.
Published: (2024-02-01)

The role of chaperone-mediated autophagy in drug resistance
by: Ana Beatriz da Silva Teixeira, et al.
Published: (2024-05-01)

Synergistic effect of perampanel with temozolomide on glioblastoma cells in vivo
by: Takuma Nishide, et al.
Published: (2025-03-01)

Exploring the role of Nrf2 signaling in glioblastoma multiforme
by: Wireko Andrew Awuah, et al.
Published: (2022-09-01)

Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors
by: Supriya Mallick, et al.
Published: (2015-01-01)

Response to Temozolomide in patients with metastatic melanoma in a third level medical facility
by: Selene Mejía-Cabrera, et al.
Published: (2022-03-01)

A Multicenter Randomized Bioequivalence Study of a Novel Ready-to-Use Temozolomide Oral Suspension vs. Temozolomide Capsules
by: François Ducray, et al.
Published: (2023-11-01)

Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights
by: Hengzeng Li, et al.
Published: (2025-06-01)

Molecular Mechanisms of KDELC2 on Glioblastoma Tumorigenesis and Temozolomide Resistance
by: Yu-Ling Tsai, et al.
Published: (2020-09-01)

Temozolomide Chronotherapy in Glioma: A Systematic Review
by: Jason L. Jia, et al.
Published: (2023-02-01)

S-1/temozolomide versus S-1/temozolomide plus thalidomide in advanced pancreatic and non-pancreatic neuroendocrine tumours (STEM): A randomised, open-label, multicentre phase 2 trial
by: Yihebali Chi, et al.
Published: (2022-12-01)

Long term survival in a patient with recurrent metastatic Ewing sarcoma treated with irinotecan and temozolomide
by: Hakan Gelincik, et al.
Published: (2016-12-01)

Vincristine, Irinotecan, and Temozolomide in Patients With Relapsed/Refractory Neuroblastoma
by: Jia Zhu, et al.
Published: (2022-03-01)

Integrins and p53 pathways in glioblastoma resistance to temozolomide
by: Monique eDontenwill, et al.
Published: (2012-10-01)

Targeting of temozolomide using magnetic nanobeads: an in vitro study
by: Berna Gürten, et al.
Published: (2020-09-01)

Survival benefits of hypofractionated radiotherapy combined with temozolomide or temozolomide plus bevacizumab in elderly patients with glioblastoma aged ≥ 75 years
by: Makoto Ohno, et al.
Published: (2019-11-01)

Comparison of multi-cycle and standard-cycle temozolomide chemotherapies in patients with glioblastoma undergoing surgery and successive radiotherapy
by: Yuan Fu, et al.
Published: (2023-06-01)

Down-Regulation of CEND1 Expression Contributes to The Progression and Temozolomide Resistance of Glioma
by: Houjun Zhou, et al.
Published: (2023-04-01)

TTK Protein Kinase promotes temozolomide resistance through inducing autophagy in glioblastoma
by: Jian Yu, et al.
Published: (2022-07-01)

Temozolomide-associated blepharoconjunctivitis: a case report
by: Tom Kornhauser, et al.
Published: (2024-04-01)

Meningeal seeding from glioblastoma multiforme treated with radiotherapy and temozolomide
by: Lu-Ting Kuo, et al.
Published: (2017-01-01)

Is Autophagy Inhibition in Combination with Temozolomide a Therapeutically Viable Strategy?
by: Ahmed M. Elshazly, et al.
Published: (2023-02-01)

Should CD4 Levels be Monitored in a Patient on Temozolomide?
by: Sriram Gonakoti, et al.
Published: (2021-03-01)

99mTc-Tetrofosmin uptake correlates with the sensitivity of glioblastoma cell lines to temozolomide
by: George Alexiou, et al.
Published: (2017-01-01)

Radiotherapy with or without temozolomide in elderly patients aged ≥ 70 years with glioblastoma
by: Evrim Metcalfe, et al.
Published: (2016-08-01)

MicroRNAs as the pivotal regulators of Temozolomide resistance in glioblastoma
by: Mahsa Palizkaran Yazdi, et al.
Published: (2024-07-01)

Synergistic Effects of Temozolomide and Doxorubicin in the Treatment of Glioblastoma Multiforme: Enhancing Efficacy through Combination Therapy
by: Laxmi Dhungel, et al.
Published: (2024-02-01)

Considering the Experimental Use of Temozolomide in Glioblastoma Research
by: Verena J. Herbener, et al.
Published: (2020-06-01)

Efficacy of systemic temozolomide‐activated phage‐targeted gene therapy in human glioblastoma
by: Justyna Magdalena Przystal, et al.
Published: (2019-02-01)

Iloperidone and Temozolomide Synergistically Inhibit Growth, Migration and Enhance Apoptosis in Glioblastoma Cells
by: Sahar Mubeen, et al.
Published: (2024-05-01)

Panobinostat Potentiates Temozolomide Effects and Reverses Epithelial–Mesenchymal Transition in Glioblastoma Cells
by: Alejandro Urdiciain, et al.
Published: (2018-02-01)

Delayed but Complete Response following Oral Temozolomide Treatment in Melanoma Leptomeningeal Carcinomatosis
by: Andreas F. Hottinger, et al.
Published: (2011-04-01)

Severe pneumocystis jiroveci pneumonia in a patient on temozolomide therapy: A case report and review of literature
by: Babar Ahmad Khan, MD, et al.
Published: (2017-01-01)

Kalata B1 Enhances Temozolomide Toxicity to Glioblastoma Cells
by: Samantha L. Gerlach, et al.
Published: (2024-09-01)

Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas
by: Chun Wang, et al.
Published: (2023-05-01)

Gossypol Suppresses Growth of Temozolomide-Resistant Glioblastoma Tumor Spheres
by: Hee Yeon Kim, et al.
Published: (2019-10-01)